Skinny Labels, Big Savings Act

HR6485, the Skinny Labels, Big Savings Act, was introduced in the House on December 5, 2025 by Rep. Cline (R-VA) and referred to the House Judiciary Committee. A companion bill (S43) exists in the Senate. This is an early-stage bill — it has not had a hearing, markup, or floor vote. The legislative path is long and uncertain, but the existence of a Senate companion and bipartisan cosponsorship (Rep. Lofgren, D-CA, is an original cosponsor) gives it moderate momentum compared to a typical single-sponsor bill. The bill amends 35 U.S.C. 271 to explicitly state that submitting a skinny label application, promoting or marketing a drug with that approved label, and describing it as a generic or therapeutically equivalent is not infringement of a method-of-use patent — provided the marketing does not reference the patented indication. This directly overturns the GlaxoSmithKline v. Teva Pharmaceuticals USA, Inc. (2021) Federal Circuit ruling, which held that generic manufacturers could be liable for induced infringement when marketing skinny label generics for non-patented uses. There is no direct funding authorization or appropriation in this bill — it is a regulatory and legal change, not a spending bill. The economic impact flows from reduced litigation costs for generic makers and accelerated generic/biosimilar entry into profitable drug markets. This structurally benefits generic manufacturers (TEVA, VTRS) by protecting their skinny label revenue streams and reducing legal risk for future launches. It structurally harms brand manufacturers (AMGN, PFE, JNJ, MRK) by removing a legal tool they used to delay generic competition for non-patented uses of their blockbuster drugs. Real market data from April 2026 shows generic makers outperforming brand manufacturers. TEVA surged +17.1% in 30 days to $35.27 — near its 52-week high of $37.35 — with a notable spike from $31.62 on April 28 to $35.38 on April 29. VTRS gained +11.4% over 30 days to $15.05. In contrast, brand manufacturers all declined: AMGN -1.3%, PFE -4.49%, JNJ -5.47%, and MRK -6.93% over the same period. This price action is consistent with market anticipation of legislative progress on the Skinny Labels bill, though other factors (earnings, pipeline news, broader market) also contribute. Next steps: The bill must clear the House Judiciary Committee (likely a hearing in Q3 2026), pass the House floor, be reconciled with S43 (if that companion advances), and be signed by the President. Given the 2026 midterm elections narrowing the legislative calendar, passage is not guaranteed this Congress. However, the bipartisan nature and narrow scope increase its chances relative to broader drug pricing legislation.